CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma
暂无分享,去创建一个
Ruibin Xi | Q. Gao | Ya Cao | Jia Fan | Jian Zhou | Jieyi Shi | Li-jie Ma | Zhen-Bin Ding | A. Ke | P. Dong | Meng Duan | Shu Zhang | Liangqing Dong | Bohao Zheng | Zhi-chao Wang | Yang Shi | Xiaoming Zhang | Zhao Zhang | Xiao-Ying Wang | Long-Zi Liu | Zhen–Bin Ding
[1] W. Hassan,et al. Interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma , 2017, Cytokine.
[2] U. Grohmann,et al. The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. , 2017, Current opinion in pharmacology.
[3] Edward F. Chang,et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.
[4] A. Jemal,et al. Disparities in liver cancer occurrence in the United States by race/ethnicity and state , 2017, CA: a cancer journal for clinicians.
[5] M. Kudo,et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.
[6] Weiping Zou,et al. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.
[7] Y. Zhuang,et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway , 2017, Gut.
[8] D. Saul,et al. The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia , 2017, Leukemia.
[9] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[10] S. Qiu,et al. CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis , 2016, Oncotarget.
[11] D. Kuang,et al. Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma , 2016, Nature communications.
[12] I. Ng,et al. Hypoxia induces myeloid‐derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C‐C motif) ligand 26 , 2016, Hepatology.
[13] D. Kuang,et al. Polarization of Tissue-Resident TFH-Like Cells in Human Hepatoma Bridges Innate Monocyte Inflammation and M2b Macrophage Polarization. , 2016, Cancer discovery.
[14] H. Date,et al. Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis , 2016, Clinical Cancer Research.
[15] Ya Cao,et al. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. , 2016, Gastroenterology.
[16] Ya Cao,et al. miR‐28‐5p‐IL‐34‐macrophage feedback loop modulates hepatocellular carcinoma metastasis , 2016, Hepatology.
[17] Peng Zhang,et al. CCL15 overexpression predicts poor prognosis for hepatocellular carcinoma , 2016, Hepatology International.
[18] Xuehao Wang,et al. Chemokine CCL15 Mediates Migration of Human Bone Marrow‐Derived Mesenchymal Stem Cells Toward Hepatocellular Carcinoma , 2016, Stem cells.
[19] Yukio Fujiwara,et al. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. , 2016, Advanced drug delivery reviews.
[20] Jing Wu,et al. CCL15/CCR1 axis is involved in hepatocellular carcinoma cells migration and invasion , 2016, Tumor Biology.
[21] Jing-quan Li,et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma , 2015, Gut.
[22] T. Welling,et al. Myeloid cells in hepatocellular carcinoma , 2015, Hepatology.
[23] M. Taketo,et al. Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15–CCR1 Chemokine Axis , 2015, Clinical Cancer Research.
[24] Dmitri D. Pervouchine,et al. The human transcriptome across tissues and individuals , 2015, Science.
[25] M. Mason,et al. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer , 2014, Oncoimmunology.
[26] F. Tacke,et al. Roles for chemokines in liver disease. , 2014, Gastroenterology.
[27] G. Giannelli,et al. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment , 2014, Gut.
[28] E. Hatano,et al. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. , 2013, Gastroenterology.
[29] S. Qiu,et al. Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.
[30] L. McShane,et al. Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] H. Guo,et al. Identification of serum CCL15 in hepatocellular carcinoma , 2013, British Journal of Cancer.
[32] T. Greten,et al. Cellular Immune Suppressor Mechanisms in Patients with Hepatocellular Carcinoma , 2012, Digestive Diseases.
[33] Xianghuo He,et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. , 2012, Cancer research.
[34] V. Seshan,et al. A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.
[35] Q. Hamid,et al. Expression and regulation of CCL15 by human airway smooth muscle cells , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[36] S. Qiu,et al. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. , 2011, Journal of hepatology.
[37] D. Kuang,et al. Tumor-Activated Monocytes Promote Expansion of IL-17–Producing CD8+ T Cells in Hepatocellular Carcinoma Patients , 2010, The Journal of Immunology.
[38] Minshan Chen,et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells , 2010, Hepatology.
[39] Jing Xu,et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.
[40] Zhao-You Tang,et al. Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion. , 2007, Biochemical and biophysical research communications.
[41] X. Wang,et al. The role of cytokines in hepatocellular carcinoma , 2006, Journal of leukocyte biology.
[42] Yan Li,et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics , 2004, Journal of Cancer Research and Clinical Oncology.
[43] Ji Su Kim,et al. Expression patterns of cytokines and chemokines genes in human hepatoma cells. , 2002, Yonsei medical journal.